An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 05 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 09 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.